Published in Br J Pharmacol on August 01, 1984
5-Carboxamide tryptamine, a compound with high affinity for 5-hydroxytryptamine1 binding sites, dilates arterioles and constricts arteriovenous anastomoses. Br J Pharmacol (1985) 1.25
5-Hydroxytryptamine-induced tachycardia in the pig: possible involvement of a new type of 5-hydroxytryptamine receptor. Br J Pharmacol (1988) 1.25
Role of 5-HT1-like receptors in the reduction of porcine cranial arteriovenous anastomotic shunting by sumatriptan. Br J Pharmacol (1991) 0.97
Canine external carotid vasoconstriction to methysergide, ergotamine and dihydroergotamine: role of 5-HT1B/1D receptors and alpha2-adrenoceptors. Br J Pharmacol (1999) 0.94
Carotid haemodynamics in pigs during infusions of 8-OH-DPAT: reduction in arteriovenous shunting is mediated by 5-HT1-like receptors. Br J Pharmacol (1989) 0.91
5-HT2 receptor antagonists and migraine therapy. J Neurol (1991) 0.87
Nimodipine-induced changes in the distribution of carotid blood flow and cardiac output in pentobarbitone-anaesthetized pigs. Br J Pharmacol (1986) 0.86
Carotid vascular effects of ergotamine and dihydroergotamine in the pig: no exclusive mediation via 5-HT1-like receptors. Br J Pharmacol (1991) 0.85
Pharmacology of antimigraine drugs. J Neurol (1991) 0.79
Bisoprolol improves perfusion of ischaemic myocardium in anaesthetized pigs. Br J Pharmacol (1988) 0.75
Two kinds of tryptamine receptor. Br J Pharmacol Chemother (1957) 7.63
Relation of structure to function of the tissues of the wall of blood vessels. Physiol Rev (1954) 5.17
Vascular effects of ketanserin (R 41 468), a novel antagonist of 5-HT2 serotonergic receptors. J Pharmacol Exp Ther (1981) 3.47
Multiple serotonin receptors: differential binding of [3H]5-hydroxytryptamine, [3H]lysergic acid diethylamide and [3H]spiroperidol. Mol Pharmacol (1979) 2.89
Selective vasoconstriction in carotid vascular bed by methysergide: possible relevance to its antimigraine effect. Eur J Pharmacol (1974) 2.04
Evidence for two types of excitatory receptor for 5-hydroxytryptamine in dog isolated vasculature. Br J Pharmacol (1980) 1.86
The effects of mianserin hydrochloride on the vascular responses evoked by 5-hydroxytryptamine and related vasoactive substances. Eur J Pharmacol (1971) 1.49
Prophylactic and therapeutic properties of 1-methyl-lysergic acid butanolamide in migraine. Int Arch Allergy Appl Immunol (1959) 1.48
Evidence for common pharmacological properties of [3H]5-hydroxytryptamine binding sites, presynaptic 5-hydroxytryptamine autoreceptors in CNS and inhibitory presynaptic 5-hydroxytryptamine receptors on sympathetic nerves. Naunyn Schmiedebergs Arch Pharmacol (1983) 1.43
Pharmacological analysis of 5-hydroxytryptamine receptors in isolated intracranial and extracranial vessels of cat and man. Circ Res (1978) 1.42
Evidence for 5-HT2 receptors mediating contraction in vascular smooth muscle. J Pharmacol Exp Ther (1981) 1.37
NORMAL ARTERIOVENOUS ANASTOMOSES. Medicine (Baltimore) (1963) 1.32
Computer programs for the radioactive microsphere technique. Determination of regional blood flows and other haemodynamic variables in different experimental circumstances. Comput Programs Biomed (1980) 1.29
The effect of ergotamine on tissue blood flow and the arteriovenous shunting of radioactive microspheres in the head. Br J Pharmacol (1978) 1.22
Arteriovenous anastomoses in the external ear. Q J Exp Physiol Cogn Med Sci (1956) 1.22
Capillary diameter and geometry in cardiac and skeletal muscle studied by means of corrosion casts. Microvasc Res (1983) 1.20
Redistribution by 5-hydroxytryptamine of carotid arterial blood at the expense of arteriovenous anastomotic blood flow. J Physiol (1982) 1.15
Role of some biogenic substances in migraine and relevant mechanism in antimigraine action of ergotamine--studies in an experimental model for migraine. Headache (1974) 1.12
Antimigraine drugs and cranial arteriovenous shunting in the cat. Neurology (1980) 1.01
Arteriovenous shunting and migraine. Res Clin Stud Headache (1978) 0.97
Modification of the vasomotor actions of methysergide in the femoral arterial bed of the anaesthetized dog by changes in sympathetic nerve activity. J Auton Pharmacol (1981) 0.96
Capillary and shunt blood flow in the nasal mucosa of the cat. Acta Otolaryngol (1975) 0.94
Regional and systemic haemodynamic changes evoked by 5-hydroxytryptamine in awake and anaesthetized rabbits. Eur J Pharmacol (1978) 0.91
ARTERIOVENOUS SHUNTS IN THE BLOOD SUPPLY TO THE BRAINS OF SOME COMMON LABORATORY ANIMALS--WITH SPECIAL ATTENTION TO THE RETE MIRABILE CONJUGATUM IN THE CAT. J Comp Neurol (1963) 0.90
The effects of humoral agents and antimigraine drugs on the cranial circulation of the monkey. Res Clin Stud Headache (1976) 0.89
Vascular effects of ergot alkaloids: a study on human basilar arteries. Gen Pharmacol (1983) 0.86
Antagonism by methysergide of vascular effects of 5-hydroxytryptamine in man. Br J Pharmacol Chemother (1967) 0.86
Hypotensive activity of serotonin receptor agonists in rats is related to their affinity for 5-HT1 receptors. Eur J Pharmacol (1983) 0.84
Diameter of arterial microvessels trapping 8--10 micron, 15 micron and 25 micron microspheres as determined by vital microscopy of the hamster cheek pouch. Invest Radiol (1978) 0.82
The influence of methysergide on 5-hydroxytryptamine-induced changes in regional distribution of blood flow. J Pharm Pharmacol (1978) 0.81
Effect of ergotamine on cranial arteriovenous shunting in experiments with constant flow perfusion. Eur J Pharmacol (1979) 0.80
Capillary size, density and ultrastructure in brain of rats with urease-induced hyperammonaemia. Acta Neurol Scand (1980) 0.77
International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol Rev (1994) 7.11
Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology (1986) 5.83
Myocardial protection by brief ischemia in noncardiac tissue. Circulation (1996) 2.91
Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism. Circulation (1995) 2.25
Selective vasoconstriction in carotid vascular bed by methysergide: possible relevance to its antimigraine effect. Eur J Pharmacol (1974) 2.04
Cardiac renin and angiotensins. Uptake from plasma versus in situ synthesis. Hypertension (1994) 1.87
Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs (2000) 1.54
Ergotamine in the acute treatment of migraine: a review and European consensus. Brain (2000) 1.52
The effects of mianserin hydrochloride on the vascular responses evoked by 5-hydroxytryptamine and related vasoactive substances. Eur J Pharmacol (1971) 1.49
Craniovascular selectivity of eletriptan and sumatriptan in human isolated blood vessels. Neurology (2000) 1.47
Ischaemic preconditioning by partial occlusion without intermittent reperfusion. Cardiovasc Res (1994) 1.44
Porcine carotid vascular effects of eletriptan (UK-116,044): a new 5-HT1B/1D receptor agonist with anti-migraine activity. Naunyn Schmiedebergs Arch Pharmacol (1998) 1.42
Bradykinin-induced contraction of human peripheral airways mediated by both bradykinin beta 2 and thromboxane prostanoid receptors. Am J Respir Crit Care Med (1994) 1.41
Coronary side-effect potential of current and prospective antimigraine drugs. Circulation (1998) 1.36
Intrarenal angiotensin II: interstitial and cellular levels and site of production. Kidney Int (2001) 1.36
Mediation of 5-hydroxytryptamine-induced tachycardia in the pig by the putative 5-HT4 receptor. Br J Pharmacol (1990) 1.31
Computer programs for the radioactive microsphere technique. Determination of regional blood flows and other haemodynamic variables in different experimental circumstances. Comput Programs Biomed (1980) 1.29
5-Carboxamide tryptamine, a compound with high affinity for 5-hydroxytryptamine1 binding sites, dilates arterioles and constricts arteriovenous anastomoses. Br J Pharmacol (1985) 1.25
5-Hydroxytryptamine-induced tachycardia in the pig: possible involvement of a new type of 5-hydroxytryptamine receptor. Br J Pharmacol (1988) 1.25
On serotonin and migraine: a clinical and pharmacological review. Cephalalgia (1993) 1.23
The effect of ergotamine on tissue blood flow and the arteriovenous shunting of radioactive microspheres in the head. Br J Pharmacol (1978) 1.22
Angiotensin production by the heart: a quantitative study in pigs with the use of radiolabeled angiotensin infusions. Circulation (1998) 1.16
Long-term endothelial dysfunction is more pronounced after stenting than after balloon angioplasty in porcine coronary arteries. J Am Coll Cardiol (1998) 1.16
Redistribution by 5-hydroxytryptamine of carotid arterial blood at the expense of arteriovenous anastomotic blood flow. J Physiol (1982) 1.15
Mechanism of selective cardiac vagolytic action of pancuronium bromide. Specific blockade of cardiac muscarinic receptors. Eur J Pharmacol (1970) 1.15
Oxidative epithelial damage produces hyperresponsiveness of human peripheral airways. Am J Respir Crit Care Med (1994) 1.14
Characterization of putative 5-HT7 receptors mediating tachycardia in the cat. Br J Pharmacol (1997) 1.14
Mannose 6-phosphate receptor-mediated internalization and activation of prorenin by cardiac cells. Hypertension (1997) 1.14
Proto-oncogene expression in porcine myocardium subjected to ischemia and reperfusion. Circ Res (1992) 1.13
Angiotensin II type 1 (AT1) receptor-mediated accumulation of angiotensin II in tissues and its intracellular half-life in vivo. Hypertension (1997) 1.13
Role of some biogenic substances in migraine and relevant mechanism in antimigraine action of ergotamine--studies in an experimental model for migraine. Headache (1974) 1.12
Antimigraine drug sumatriptan increases blood flow velocity in large cerebral arteries during migraine attacks. Neurology (1992) 1.10
Analysis of the heart rate effects of 5-hydroxytryptamine in the cat; mediation of tachycardia by 5-HT1-like receptors. Naunyn Schmiedebergs Arch Pharmacol (1985) 1.10
Transmission of ultrasonic contrast through the lungs. Ultrasound Med Biol (1981) 1.07
Has melatonin a future as a cardioprotective agent? Cardiovasc Drugs Ther (2001) 1.07
Biocompatibility of phosphorylcholine coated stents in normal porcine coronary arteries. Heart (2000) 1.06
Cardiovascular profile of pimobendan, a benzimidazole-pyridazinone derivative with vasodilating and inotropic properties. Eur J Pharmacol (1986) 1.06
Antiarrhythmic and hemodynamic actions of flecainide acetate (R-818) in the ischemic porcine heart. J Cardiovasc Pharmacol (1980) 1.05
Further characterization, by use of tryptamine and benzamide derivatives, of the putative 5-HT4 receptor mediating tachycardia in the pig. Br J Pharmacol (1991) 1.05
Increasing arterial wall injury after long-term implantation of two types of stent in a porcine coronary model. Eur Heart J (1998) 1.04
Time course and mechanism of myocardial catecholamine release during transient ischemia in vivo. Circulation (2000) 1.04
The current endothelin receptor classification: time for reconsideration? Trends Pharmacol Sci (1994) 1.03
Antimigraine drugs and cranial arteriovenous shunting in the cat. Neurology (1980) 1.01
Tissue blood flow and localization of arteriovenous anastomoses in pigs with microspheres of four different sizes. Pflugers Arch (1985) 1.00
Excitatory 5-hydroxytryptamine receptors in the cat urinary bladder are of the M- and 5-HT2-type. J Auton Pharmacol (1985) 1.00
N-(3-acetylaminophenyl)piperazine hydrochloride (BEA 1654), a putative 5-HT1 agonist, causes constriction of arteriovenous anastomoses and dilatation of arterioles. Eur J Pharmacol (1985) 1.00
Role of adenosine in the regulation of coronary blood flow in swine at rest and during treadmill exercise. Am J Physiol (1998) 1.00
A comparison of cardiovascular and smooth muscle effects of 5-hydroxytryptamine and 5-carboxamidotryptamine, a selective agonist of 5-HT1 receptors. Arch Int Pharmacodyn Ther (1985) 1.00
Angiotensin II induces hypertrophy of human airway smooth muscle cells: expression of transcription factors and transforming growth factor-beta1. Am J Respir Cell Mol Biol (1998) 1.00
Haemodynamic changes and acetylcholine-induced hypotensive responses after NG-nitro-L-arginine methyl ester in rats and cats. Br J Pharmacol (1991) 0.99
Angiotensin II-mediated growth and antigrowth effects in cultured neonatal rat cardiac myocytes and fibroblasts. J Mol Cell Cardiol (1997) 0.98
Autonomic control of vasomotion in the porcine coronary circulation during treadmill exercise: evidence for feed-forward beta-adrenergic control. Circ Res (1998) 0.98
Redistribution of carotid artery blood flow by 5-HT: effects of the 5-HT2 receptor antagonists ketanserin and Wal 1307. Eur J Pharmacol (1984) 0.97
Serum levels of tumor necrosis factor determine the fatal or non-fatal course of endotoxic shock. Immunol Lett (1991) 0.97
Role of 5-HT1-like receptors in the reduction of porcine cranial arteriovenous anastomotic shunting by sumatriptan. Br J Pharmacol (1991) 0.97
Arteriovenous shunting and migraine. Res Clin Stud Headache (1978) 0.97
Endothelin receptors in the human coronary artery, ventricle and atrium. A quantitative autoradiographic analysis. Naunyn Schmiedebergs Arch Pharmacol (1993) 0.97
Heterogeneity of endothelin/sarafotoxin receptors mediating contraction of the human isolated saphenous vein. Eur J Pharmacol (1993) 0.96
Comparative effects of the antimigraine drugs sumatriptan and ergotamine on the distribution of cardiac output in anaesthetized pigs. Cephalalgia (1992) 0.96
Angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade prevent cardiac remodeling in pigs after myocardial infarction: role of tissue angiotensin II. Circulation (2000) 0.95
Ergotamine-induced constriction of cranial arteriovenous anastomoses in dogs pretreated with phentolamine and pizotifen. Cephalalgia (1983) 0.95
5-Hydroxytryptamine-induced contractions of the human isolated saphenous vein: involvement of 5-HT2 and 5-HT1D-like receptors, and a comparison with grafted veins. Naunyn Schmiedebergs Arch Pharmacol (1992) 0.94
Analysis of alpha 1L-adrenoceptor pharmacology in rat small mesenteric artery. Br J Pharmacol (1999) 0.94
Identification of acetylcholine, histamine, and 5-hydroxytryptamine in Girardinia heterophylla (Decne.). Can J Physiol Pharmacol (1966) 0.94
Pharmacological aspects of experimental headache models in relation to acute antimigraine therapy. Eur J Pharmacol (1999) 0.94
Investigation of the role of 5-HT1B and 5-HT1D receptors in the sumatriptan-induced constriction of porcine carotid arteriovenous anastomoses. Br J Pharmacol (1999) 0.94
Clinical and experimental effects of sumatriptan in humans. Trends Pharmacol Sci (1993) 0.93
Low-dose aspirin inhibits platelet-induced contraction of the human isolated coronary artery. A role for additional 5-hydroxytryptamine receptor antagonism against coronary vasospasm? Circulation (1994) 0.93
The selective bradycardic effects of zatebradine (UL-FS 49) do not adversely affect left ventricular function in conscious pigs with chronic coronary artery occlusion. Cardiovasc Drugs Ther (1992) 0.92
Subcellular localization of angiotensin II in kidney and adrenal. J Hypertens (2001) 0.92
The canine external carotid vasoconstrictor 5-HT1 receptor: blockade by 5-HT1B (SB224289), but not by 5-HT1D (BRL15572) receptor antagonists. Eur J Pharmacol (1998) 0.92
Bradykinin potentiation by angiotensin-(1-7) and ACE inhibitors correlates with ACE C- and N-domain blockade. Hypertension (2001) 0.92
Role of K(ATP)(+) channels in regulation of systemic, pulmonary, and coronary vasomotor tone in exercising swine. Am J Physiol Heart Circ Physiol (2001) 0.92
The effects of alinidine, an N-allyl derivative of clonidine, on regional myocardial perfusion and performance in the pig with or without atrial pacing. Eur J Pharmacol (1980) 0.92
Cardiac remodeling and contractile function in acid alpha-glucosidase knockout mice. Physiol Genomics (2001) 0.91
Vasoconstriction by in situ formed angiotensin II: role of ACE and chymase. Cardiovasc Res (1999) 0.91
Nicorandil-induced changes in the distribution of cardiac output and coronary blood flow in pigs. Naunyn Schmiedebergs Arch Pharmacol (1987) 0.91
Carotid haemodynamics in pigs during infusions of 8-OH-DPAT: reduction in arteriovenous shunting is mediated by 5-HT1-like receptors. Br J Pharmacol (1989) 0.91
Nitric oxide contributes to the regulation of vasomotor tone but does not modulate O(2)-consumption in exercising swine. Cardiovasc Res (2000) 0.91
Regional and systemic haemodynamic changes evoked by 5-hydroxytryptamine in awake and anaesthetized rabbits. Eur J Pharmacol (1978) 0.91
Reduction in thrombotic events with heparin-coated Palmaz-Schatz stents in normal porcine coronary arteries. Circulation (1996) 0.91
Coordinated expression of heme oxygenase-1 and ubiquitin in the porcine heart subjected to ischemia and reperfusion. Mol Cell Biochem (1996) 0.91
Acute systemic and regional hemodynamic effects of felodipine, a new calcium antagonist, in conscious renal hypertensive rabbits. J Cardiovasc Pharmacol (1984) 0.91
Domestic pigs in the study of myocardial ischemia. Eur Heart J (1983) 0.90
Effects of MDL 72222 and methiothepin on carotid vascular responses to 5-hydroxytryptamine in the pig: evidence for the presence of "5-hydroxytryptamine1-like" receptors. Naunyn Schmiedebergs Arch Pharmacol (1986) 0.90
The role of several alpha(1)- and alpha(2)-adrenoceptor subtypes mediating vasoconstriction in the canine external carotid circulation. Br J Pharmacol (2001) 0.90
Coronary stenting with a new, radiopaque, balloon-expandable endoprosthesis in pigs. Circulation (1991) 0.89
Systemic and regional myocardial responses to AR-L 115 BS, a positive inotropic imidazo-pyridine, in the absence or in the presence of the bradycardiac action of alinidine. Basic Res Cardiol (1981) 0.89